Rotella Capital Management’s Inovio Pharmaceuticals INO Stock Holding History

Rotella Capital Management’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-5,311	Closed	-$428K	–	125
2015 Q4	$428K	Sell	5,311 -14,781	-74%	-$1.18M	0.38%	92
2015 Q3	$1.39M	Buy	20,092 +18,939	+1,643%	+$1.65M	0.45%	26
2015 Q2	$113K	Sell	1,153 -10,670	-90%	-$1.14M	0.09%	255
2015 Q1	$1.16M	Buy	+11,823	New	+$1.15M	0.97%	8
2014 Q3	–	Sell	-1,246	Closed	-$163K	–	360
2014 Q2	$163K	Buy	+1,246	New	+$147K	0.14%	146

Other funds holding INO

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

SIP

Stoneridge Investment Partners Radnor, Pennsylvania $138M AUM 7.66% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Rotella Capital Management's INO Position: Q1 2016 in Review

Rotella Capital Management sold out of Inovio Pharmaceuticals (INO) in Q1 2016, closing a stake of 5,311 shares — an estimated $428K sold.

Rotella Capital Management first reported a position in INO in Q2 2014 and held it in 5 quarters. The position peaked at $1.39M in Q3 2015. 115 funds tracked by Wall St. Rank hold INO as of Q1 2016.

Rotella Capital Management reported no remaining Inovio Pharmaceuticals position as of Q1 2016 after selling out during the quarter.
Rotella Capital Management sold 5,311 Inovio Pharmaceuticals shares in Q1 2016, an estimated $428K.
Rotella Capital Management first reported a position in Inovio Pharmaceuticals in Q2 2014 and held it in 5 quarters.
Rotella Capital Management's Inovio Pharmaceuticals position peaked at $1.39M in Q3 2015.
115 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q1 2016.

Based on Rotella Capital Management's 13F filing for Q1 2016, filed 13 May 2016.